Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.52 |
| ▸ | PPARD | Q03181 | 11/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549843 | 0.91 | PPARD (0.42) | PPARAPPARDPPARGCNR2EPHX2 | |
| SCHEMBL1549154 | 0.89 | PPARA (0.46) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1549801 | 0.89 | PPARA (0.46) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1549225 | 0.88 | PPARA (0.45) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1379386 | 0.86 | PPARA (0.69) | PPARAPPARDPPARGCNR2 | |
| SCHEMBL1549678 | 0.84 | PPARA (0.47) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1549559 | 0.82 | PPARA (0.51) | PPARAPPARDPPARG | |
| SCHEMBL1550163 | 0.80 | EPHX2 (0.40) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1550809 | 0.80 | EPHX2 (0.40) | PPARAPPARDPPARGEPHX2NR1H4 | |
| SCHEMBL1549989 | 0.80 | EPHX2 (0.39) | PPARAPPARDPPARGEPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4745244-B2 | — | — | 2011-08-10 | — | — | JP | claimed |
| EP-2314576-A1 | Phenyl derivatives as PPAR agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2011-04-27 | — | — | EP | claimed |
| US-7115611-B2 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1682508-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | claimed |
| WO-2005049573-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | claimed |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | claimed |
| EP-2314576-A1 | Phenyl derivatives as PPAR agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-7115611-B2 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1682508-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049573-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | PPARA 2/4885PPARD 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.